ClinicalTrials.gg
CompletedNCT03950674Updated Jun 10, 2024Results posted

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

A Phase 3 interventional study of Pembrolizumab 200 mg and Cisplatin in Non-Small-Cell Lung Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Feb 2016, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
80th of 127
40 · median 65
Started
2016
with 15 others
Phase 3
28 of 127
4 open now
Registered
63rd of 127
by date
Lead sponsor
27 of 127
Merck Sharp & Dohme LLC

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 80th largest by enrollment, is one of 16 that started in 2016, is one of 28 in phase 3, and was the 63rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in adult Japanese participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease. Participants will be randomly assigned to receive pembrolizumab combined with pemetrexed/platinum (Investigators choice of cisplatin or carboplatin), OR pemetrexed/platinum (Investigators choice of cisplatin or carboplatin).

With Amendment 11 (effective date 31-Jan-2022), once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.

The primary hypothesis is that pembrolizumab in combination with pemetrexed/platinum chemotherapy prolongs Progression-Free Survival (PFS) and Overall Survival (OS) compared to pemetrexed/platinum chemotherapy alone.

Read the detailed description

The MK-3475-189-Japan Extension Study will be identical to the global study (e.g. inclusion and exclusion criteria, study primary and secondary outcome measures and study procedures).

The MK-3475-189-Japanese Extension Study enrolled a total of 30 participants and the analyses included 10 participants (pembrolizumab =4; control = 6) that had been previously enrolled in the MK-3475-189 global study (NCT02578680), resulting in a total of 40 participants.

03

Conditions studied

  • Non-Small-Cell Lung Carcinoma

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
  • Non-Small-Cell Lung Cancer (NSCLC)
  • PD1
  • PD-1
  • PDL1
  • PD-L1
  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a -confirmed or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.
  • Has confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated.
  • Has .
  • Has not received prior systemic treatment for their advanced/ NSCLC.
  • Can provide tumor tissue.
  • Has a of at least 3 months.
  • Has a performance status of 0 or 1 on the (ECOG) Performance Status.
  • Has adequate organ function
  • If female of , is willing to use adequate for the course of the study through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.
  • If male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.

Exclusion criteria

Exclusion Criteria:

  • Has predominantly squamous cell histology NSCLC.
  • Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.
  • Before the first dose of study medication: a) Has received prior systemic cytotoxic chemotherapy for disease, b) Has received antineoplastic biological therapy (e.g. erlotinib, crizotinib, cetuximab), c) Had major surgery (\<3 weeks prior to first dose)
  • Received radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study medication.
  • Completed palliative radiotherapy within 7 days of the first dose of study medication.
  • Is expected to require any other form of antineoplastic therapy while on study.
  • Received a live-virus vaccination within 30 days of planned start of study medication.
  • Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, peritoneal carcinomatosis.
  • Known history of prior except if participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy, except for successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Previously had a severe reaction to treatment with another monoclonal antibody (mAb).
  • Known sensitivity to any component of cisplatin, carboplatin or pemetrexed.
  • Has active disease that has required systemic treatment in past 2 years.
  • Is on chronic systemic .
  • Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
  • Is unable or unwilling to take folic acid or vitamin B12 supplementation.
  • Had prior treatment with any other anti-programmed cell death-1 (), or PD-ligand 1 (PD-L1) or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Has participated in any other pembrolizumab study and has been treated with pembrolizumab.
  • Has an active infection requiring therapy.
  • Has known history of (HIV).
  • Has known active or C.
  • Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.
  • Is a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
  • Has symptomatic ascites or pleural effusion.
  • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Pembrolizumab with Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and Pemetrexed

    Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression. Participants who receive pembrolizumab 200 mg IV Q3W for up to 2 years, but experience disease progression, are eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to another year.

    Biological: Pembrolizumab 200 mg · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Dietary Supplement: Folic acid 350-1000 μg · Dietary Supplement: Vitamin B12 1000 μg · Drug: Dexamethasone 4 mg

  • Active comparator
    Placebo with Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed

    Participants receive saline placebo IV PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression. Participants who receive saline placebo, but experience disease progression, can switch over to pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 2 years. The participants who switch over to pembrolizumab 200 mg IV Q3W, but experience disease progression, are eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to another year.

    Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Dietary Supplement: Folic acid 350-1000 μg · Dietary Supplement: Vitamin B12 1000 μg · Drug: Dexamethasone 4 mg · Drug: Saline solution

Interventions

  • IV infusion

  • IV infusion

  • IV infusion

  • IV infusion

  • Dietary supplementFolic acid 350-1000 μg

    Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

  • Dietary supplementVitamin B12 1000 μg

    Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

  • For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

  • DrugSaline solution

    IV infusion

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented.

    Time frame: Up to approximately 31 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS is presented.

    Time frame: Up to approximately 31 months

Secondary outcomes

  1. Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging

    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.

    Time frame: Up to approximately 31 months

  2. Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging

    For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR per RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented.

    Time frame: Up to approximately 31 months

  3. Number of Participants Who Experienced an Adverse Event (AE)

    An adverse event was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical product which did not necessarily have a causal relationship with this treatment. An adverse event was any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the study drug was also an adverse event. Per protocol, final analysis for this outcome measure was performed for the first course of pembrolizumab or placebo treatment. The number of participants who experienced an AE is reported.

    Time frame: Up to approximately 24 months

  4. Number of Participants Who Discontinued Any Study Drug Due to an AE

    An adverse event was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical product which did not necessarily have a causal relationship with this treatment. An adverse event was any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the study drug was also an adverse event. Per protocol, final analysis for this outcome measure was performed for the first course of pembrolizumab or placebo treatment. The number of participants who discontinued study treatment due to an AE is presented.

    Time frame: Up to approximately 21 months

Other outcomes

  1. Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria

    PFS was defined as the time from randomization to the first documented immune-related progressive disease (irPD) or death due to any cause, whichever occurred first. Per irRECIST, irPD was confirmed if any of the following are observed in 2 scans performed at least 4 weeks apart: target lesion sum of diameters remains ≥20 % and at least 5 mm absolute increase compared to nadir; non-target disease resulting in initial PD is qualitatively worse; new lesion resulting in initial irPD is qualitatively worse; additional new lesion(s) since last evaluation; or additional new non-target lesion progression since last evaluation. The PFS per irRECIST 1.1 is presented.

    Time frame: Up to approximately 31 months

07

Results

Posted Jun 11, 2020

Participant flow

The Japanese Extension study for MK-3475-189 enrolled a total of 30 participants and the analyses included 10 participants (pembrolizumab =4; control = 6) that had been previously enrolled in the global study for MK-3475-189 (NCT02578680), resulting in a total of 40 participants.

Participant flow — Overall Study
MilestonePembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Started2515
Treated2515
Switched to pembrolizumab monotherapy04
Second course treatment with pembrolizumab monotherapy10
Completed00
Not completed2515
Withdrew: Death1615
Withdrew: Participation in the study terminated by the sponsor90

Outcome measures

PrimaryProgression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
MonthsPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging16.5 (8.8 to 21.1)7.1 (4.7 to 21.4)
Statistical analysis
  • Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and Pemetrexed vs Placebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed · Log Rank · p = 0.12511 (One-sided p-value based on unstratified log-rank test) · Hazard ratio (hr): 0.62 · 95% CI 0.27 to 1.42Based on Cox regression model with treatment as a covariate stratified by PD-L1 status (≥1% vs. \<1%), platinum chemotherapy (cisplatin vs. carboplatin) \& smoking status (never vs. former/current). Pembrolizumab=numerator; Control=denominator.
PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS is presented.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Overall Survival (OS)NA (NA to NA)25.9 (11.9 to 29.0)
Statistical analysis
  • Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and Pemetrexed vs Placebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed · Log Rank · p = 0.03127 (One-sided p-value based on unstratified log-rank test) · Hazard ratio (hr): 0.29 · 95% CI 0.07 to 1.15Based on Cox regression model with treatment as a covariate stratified by PD-L1 status (≥1% vs. \<1%), platinum chemotherapy (cisplatin vs. carboplatin) \& smoking status (never vs. former/current). Pembrolizumab=numerator; Control=denominator.
SecondaryOverall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.

Time frame:
Up to approximately 31 months
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
Percentage of ParticipantsPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging56.0 (34.9 to 75.6)33.3 (11.8 to 61.6)
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR per RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
MonthsPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging13.6 (5.9 to 19.6)9.7 (3.4 to NA)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An adverse event was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical product which did not necessarily have a causal relationship with this treatment. An adverse event was any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the study drug was also an adverse event. Per protocol, final analysis for this outcome measure was performed for the first course of pembrolizumab or placebo treatment. The number of participants who experienced an AE is reported.

Time frame:
Up to approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Number of Participants Who Experienced an Adverse Event (AE)2515
SecondaryNumber of Participants Who Discontinued Any Study Drug Due to an AE

An adverse event was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical product which did not necessarily have a causal relationship with this treatment. An adverse event was any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the study drug was also an adverse event. Per protocol, final analysis for this outcome measure was performed for the first course of pembrolizumab or placebo treatment. The number of participants who discontinued study treatment due to an AE is presented.

Time frame:
Up to approximately 21 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Any Study Drug Due to an AE
ParticipantsPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Number of Participants Who Discontinued Any Study Drug Due to an AE93
Other pre-specifiedProgression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria

PFS was defined as the time from randomization to the first documented immune-related progressive disease (irPD) or death due to any cause, whichever occurred first. Per irRECIST, irPD was confirmed if any of the following are observed in 2 scans performed at least 4 weeks apart: target lesion sum of diameters remains ≥20 % and at least 5 mm absolute increase compared to nadir; non-target disease resulting in initial PD is qualitatively worse; new lesion resulting in initial irPD is qualitatively worse; additional new lesion(s) since last evaluation; or additional new non-target lesion progression since last evaluation. The PFS per irRECIST 1.1 is presented.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria
MonthsPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed
Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria13.7 (6.4 to 22.0)7.6 (2.6 to 11.9)

Adverse events

Collected over Up to approximately 80 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and Pemetrexed15/25 (60%)9/25 (36%)25/25 (100%)
Placebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed11/15 (73.3%)6/15 (40%)15/15 (100%)
Placebo Switched Over to Pembrolizumab Monotherapy4/4 (100%)1/4 (25%)4/4 (100%)
Second Course Treatment for the Pembrolizumab With Pemetrexed and Platinum Chemotherapy Arm1/1 (100%)0/1 (0%)0/1 (0%)
Second Course Treatment for the Placebo Switched Over to Pembrolizumab Monotherapy Arm———
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedPlacebo Switched Over to Pembrolizumab MonotherapySecond Course Treatment for the Pembrolizumab With Pemetrexed and Platinum Chemotherapy ArmSecond Course Treatment for the Placebo Switched Over to Pembrolizumab Monotherapy Arm
PneumonitisRespiratory, thoracic and mediastinal disorders1/250/151/40/1—
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/252/150/40/1—
PyrexiaGeneral disorders2/250/150/40/1—
DiarrhoeaGastrointestinal disorders1/251/150/40/1—
Tumour necrosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/251/150/40/1—
Cerebral haemorrhageNervous system disorders0/251/150/40/1—
Acute kidney injuryRenal and urinary disorders0/251/150/40/1—
Adrenal insufficiencyEndocrine disorders1/250/150/40/1—
Hepatic function abnormalHepatobiliary disorders1/250/150/40/1—
Bacterial infectionInfections and infestations1/250/150/40/1—
Most frequent other events
Showing 10 of 96
Most frequent other events
EventPembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedPlacebo Switched Over to Pembrolizumab MonotherapySecond Course Treatment for the Pembrolizumab With Pemetrexed and Platinum Chemotherapy ArmSecond Course Treatment for the Placebo Switched Over to Pembrolizumab Monotherapy Arm
ConstipationGastrointestinal disorders16/2511/150/40/1—
NauseaGastrointestinal disorders18/258/151/40/1—
AnaemiaBlood and lymphatic system disorders11/2510/150/40/1—
Decreased appetiteMetabolism and nutrition disorders14/259/150/40/1—
LeukopeniaBlood and lymphatic system disorders0/257/150/40/1—
White blood cell count decreasedInvestigations10/253/150/40/1—
Alanine aminotransferase increasedInvestigations9/255/150/40/1—
Dry skinSkin and subcutaneous tissue disorders9/252/150/40/1—
FatigueGeneral disorders4/255/150/40/1—
Oedema peripheralGeneral disorders2/255/150/40/1—

Baseline characteristics

The Baseline Analysis Population consisted of all randomized participants.

Age, Continuous
Age, Continuous(Years)Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedTotal
Mean59.6 ± 12.760.9 ± 11.860.1 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedTotal
Female639
Male191231
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedTotal
Hispanic or Latino000
Not Hispanic or Latino251540
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedTotal
American Indian or Alaska Native000
Asian251540
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status
Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status(Participants)Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedTotal
TPS <1%14620
TPS ≥1%10616
Not Evaluable134
Platinum Chemotherapy
Platinum Chemotherapy(Participants)Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedTotal
Cisplatin18826
Carboplatin7714
Smoking Status
Smoking Status(Participants)Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and PemetrexedPlacebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and PemetrexedTotal
Never Smoker7310
Former/Current Smoker181230
08

Study locations

10 sites
  • National Hospital Organization Nagoya Medical Center ( Site 0324)
    Nagoya, Aichi 460-0001, Japan
  • Kurume University Hospital ( Site 0326)
    Kurume, Fukuoka 830-0011, Japan
  • Hyogo Cancer Center ( Site 0325)
    Akashi, Hyogo 673-8558, Japan
  • Kanazawa University Hospital ( Site 0328)
    Kanazawa, Ishikawa 920-8641, Japan
  • Kansai Medical University Hospital ( Site 0313)
    Hirakata, Osaka 573-1191, Japan
  • Shizuoka Cancer Center Hospital and Research Institute ( Site 0322)
    Sunto-gun, Shizuoka 411-8777, Japan
  • National Hospital Organization Shikoku Cancer Center ( Site 0303)
    Matsuyama, 791-0280, Japan
  • Okayama University Hospital ( Site 0327)
    Okayama, 700-8558, Japan
  • National Cancer Center Hospital ( Site 0301)
    Tokyo, 104-0045, Japan
  • The Cancer Institute Hospital of JFCR ( Site 0323)
    Tokyo, 135-8550, Japan
09

References and documents

Publications

  • Horinouchi H, Nogami N, Saka H, Nishio M, Tokito T, Takahashi T, Kasahara K, Hattori Y, Ichihara E, Adachi N, Noguchi K, Souza F, Kurata T. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Cancer Sci. 2021 Aug;112(8):3255-3265. doi: 10.1111/cas.14980. Epub 2021 Jun 15. PubMed 34036692 ↗
  • Rolfo C, Hess LM, Jen MH, Peterson P, Li X, Liu H, Lai Y, Sugihara T, Kiiskinen U, Vickers A, Summers Y. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open. 2022 Aug;7(4):100551. doi: 10.1016/j.esmoop.2022.100551. Epub 2022 Aug 2. PubMed 35930972 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in May 2019, 38 months.

Results were first posted in Jun 2020, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 38 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2019
First posted
May 15, 2019
StartActual
Feb 22, 2016
Primary completionActual
May 20, 2019
CompletionActual
Jun 22, 2023
Results first posted
Jun 11, 2020
Last update
Jun 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03950674
Responsible party
Sponsor
First posted
May 15, 2019
Start date
Feb 22, 2016
Primary completion
May 20, 2019
Completion
Jun 22, 2023
Results posted
Jun 11, 2020
Last update
Jun 10, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion